West Pharmaceutical Services, Inc. (NYSE:WST) completed a strategic investment of $8.4 million in NanoPass, a Viola Partners portfolio company
West Makes Strategic Investment in NanoPass Technologies
EXTON, Pa., April 25, 2016 -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced a strategic investment in NanoPass Technologies Ltd. This investment will provide West with access to NanoPass’ knowledge and expertise in the growing area of intradermal drug delivery, and future collaboration opportunities to bring new products to market. West’s strategic investment will allow Nanopass to advance its clinical development efforts, and support the launch of its microneedle-based device for intradermal delivery of vaccines and drugs.
“We expect that advances in intradermal drug delivery will be critical to realizing the full potential of some of the pharmaceutical and biotech industry’s latest advancements in vaccine and immunotherapy treatments,” said Eric Resnick, Chief Technology Officer and Vice President, Innovation and Technology, West. “The microneedle technology developed by NanoPass complements our growing portfolio of drug delivery solutions at West, including our own Intradermal Adapter. We believe NanoPass has made great strides in this specialized area of drug delivery and we look forward to our partnership.”
"We are delighted to enter into this strategic partnership with West, a recognized global leader in the integrated containment and delivery of injectable drugs,” said Dr. Yotam Levin, Chief Executive, NanoPass. “We share a vision of enabling new vaccines, cancer and allergy immunotherapies with our intradermal injection technology, and envision significant synergies in production, marketing and future device developments. We could not have found a more suitable partner with the global reach, capacity and related expertise to grow NanoPass to the next level."
NanoPass is a pioneer in the development of intradermal delivery for vaccines and cancer, allergy and diabetes immunotherapy. The Company’s microneedle system, MicronJet600™ is a microneedle-based device for intradermal delivery of vaccines and drugs, which enables consistent and less painful [1,2,3] delivery of therapeutics directly into the skin. MicronJet600™ is registered for marketing in various
territories including the US FDA 510k clearance, for use by health care professionals for intradermal delivery.
NanoPass has one of the largest clinical databases in the industry for ID vaccination. It has supported numerous clinical studies in various fields including vaccines (seasonal and pandemic influenza, polio, zoster and others) with top pharmaceutical companies and the Centers for Disease Control and Prevention [1-6] and is supporting multiple cancer, allergy and diabetes immunotherapy studies on a global scale (Phase I to III). In many of these trials it was demonstrated that significant dose sparing (x5 -to x27) is achievable with the device [1,4,5,6]. Intradermal delivery is thought to harness the skin’s potent immune system to improve vaccines, and/or to dramatically reduce their dose while achieving equivalent effect. The company was founded by Dr. Shuki Yeshurun and is backed by prominent investors including IHCV, XT Hi Tech Investments, DPartners and Elcam Medical. For more information visit: www.nanopass.com.
West Pharmaceutical Services, Inc. is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Working by the side of its customers from concept to patient, West creates products that promote the efficiency, reliability and safety of the world's pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its customers from locations in North and South America, Europe, Asia and Australia. West's 2015 sales of $1.4 billion reflect the daily use of approximately 110 million of its components and devices, which are designed to improve the delivery of healthcare to patients around the world. For more information visit: www.westpharma.com.
1. Hung I et al. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine. 2012 Oct 5;30(45):6427-35
2. Abhijeet A et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial. Vaccine. 2015 Nov 27;33(48):6816-22
3. Lee H et al. Safety and efficacy of tuberculin skin testing with microneedle MicronJet600 in healthy adults. Int J Tuberc Lung Dis. 2016 Apr;20(4):500-4.
4. Levin Y et al. Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future. Hum Vaccin Immunother. 2015;11(4):991-7.
5. Beals C et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infect Dis. 2016 Apr 6. [Epub ahead of print]
6. Levin Y et al. Clinical evaluation of a novel microneedle device for intradermal delivery of an influenza vaccine: Are all delivery methods the same? Vaccine. 2014 Jul 23;32(34):4249-52